“Obesity paradox” in coronary artery disease

Ibrahim Akin, Christoph A Nienaber

Ibrahim Akin, Department of Cardiology, Universitätsmedizin Mannheim, 68167 Mannheim, Germany

Christoph A Nienaber, Cardiology and Aortic Centre, the Royal Brompton Hospital and Harefield Trust, London SW3 6NP, United Kingdom

Author contributions: Both authors contributed to this manuscript.

Conflict-of-interest statement: No conflict of interest for all authors.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Dr. Christoph A Nienaber, Professor, Cardiology and Aortic Centre, the Royal Brompton Hospital and Harefield Trust, Sydney Street, London SW3 6NP, United Kingdom. c.nienaber@rbht.nhs.uk
Telephone: +44-0207-3528121
Fax: +44-0207-3518634

Received: May 25, 2015
Peer-review started: May 27, 2015
First decision: July 10, 2015
Revised: August 4, 2015
Accepted: August 20, 2015
Article in press: August 21, 2015
Published online: October 26, 2015

Abstract

Obesity used to be among the more neglected public health problems, but has unfolded as a growing medical and socioeconomic burden of epidemic proportions. Morbid obesity is linked to traditional cardiovascular risk factors like, hypertension, hyperlipidemia and diabetes, and suspected to incur increased morbidity and mortality in the Western and even third world populations. This patient cohort is also at greater risk to develop coronary artery disease. Recent population-based registries revealed that 43% and 24% of all cases of coronary revascularization were carried out in overweight and obese patients, respectively. However, despite evidence of a positive correlation between obesity and increased cardiovascular morbidity, some authors have described a better clinical outcome in overweight and obese patients, a phenomenon they coined “obesity paradoxon”. Thus, there is an ongoing debate in light of conflicting data and the possibility of confounding bias causing misconception and challenging the “obesity paradox”. In this review article we present the current evidence and throughly discuss the validity of the “obesity paradoxon” in a variety of clinical settings.

Key words: Coronary stent; Obesity paradox; Mortality; Body mass index

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Obesity is one of the leading health problems within the last years and is associated with several cardiovascular risk factors resulting in increased prevalence of coronary artery disease as well as atherosclerotic disease in head vessels and peripheral artery system. Despite these positive correlations there are reports describing a protective effect in patients undergoing coronary revascularization. This review will enlight the potential causes and bias regarding this “obesity paradoxon” in several clinical setting and will present the latest data.

Akin I, Nienaber CA. “Obesity paradox” in coronary artery disease. World J Cardiol 2015; 7(10): 603-608 Available from: URL: http://www.wjgnet.com/1949-8462/full/v7/i10/603.htm DOI: http://dx.doi.org/10.4330/wjc.v7.i10.603

INTRODUCTION

Epidemiologic data on obesity, traditionally defined...
as a body mass index (BMI) > 30 kg/m², range in the Western population with a prevalence of up to 36.5%\(^{11}\). Prevalence in United States is up to 70% that is much higher than 40 years ago (25%)\(^{2}\). Obesity and associated disorders like arterial hypertension, dyslipidemia, diabetes mellitus and sleep apnea syndrome are linked to increased morbidity and mortality\(^{3,4}\). Common recommendation is weight loss to modify cardiovascular risk as an attempt for primary and secondary prevention of cardiovascular disease in overweight and obese patients\(^{5-7}\). Obesity is associated with increased atherosclerotic diseases, especially coronary artery disease by reduced insulin sensitivity, enhanced free fatty acid turnover, increased basal sympathetic tone, a hypercoagulable state, and finally by promotion of systemic inflammation\(^{8-10}\). Population-based data revealed that 43% and 24% of all coronary revascularization were carried out in overweight and obese patients, respectively\(^{11}\). Clinical outcome speculations should indicate that these patient cohorts would be associated with worse outcomes as compared to normal weight patients. Nevertheless, despite proven evidence of a causative association between morbidity and increased cardiovascular morbidity, previous studies have described the phenomenon of "obesity paradoxon", reporting a protective effect of obesity with regards to postoperative morbidity and mortality in patients receiving a surgical of interventional revascularization\(^{11}\). The observation of better clinical outcome is not only restricted to coronary revascularization but also in other clinical settings like acute myocardial infarction and heart failure\(^{12,13}\). With this review article we would like to give an overview and summary on the evidence of an "obesity paradoxon" in coronary artery disease.

**STABLE CORONARY ARTERY DISEASE**

Correlation of BMI with clinical endpoints in the setting of interventional coronary revascularization was first reported in 1996 from a single-center experience in patients \((n = 3571)\) receiving balloon angioplasty\(^{14}\). In-hospital outcomes revealed higher rates of mortality (2.8% vs 0.9% vs 3.7%; \(P < 0.001\)) in normal weight and obese patients as compared to overweight patients. Similar differences were seen in need for blood transfusion (11.9% vs 7.4% vs 8.4%; \(P = 0.003\)) and rise in creatinine > 1 mg/dL (3.6% vs 1.8% vs 1.8%; \(P = 0.018\)); whereas rates for myocardial infarction were not different (3.5% vs 3.4% vs 4.7%; \(P = ns\)). A total of 3634 patients from the multicenter BARI registry undergoing elective revascularization \([2108\) by interventional procedure (PCI) and 1526 by surgery (CABG)] between 1988 and 1991 were evaluated for BMI at study entry\(^{15}\). Body mass index (BMI) was associated with increased risk of a major in-hospital event just in the PCI arm. However, at five year follow-up there was a correlation between mortality and BMI only in the CABG arm. While these results from the BARI trial suggested an inverse correlation of BMI with in-hospital outcome after PCI and no such difference with long-term follow-up, Gruberg et al\(^{11}\) revealed an inverse correlation during 12-mo follow-up in 9633 patients that had been evaluated between 1994 and 1999 for mortality (10.6% vs 5.7% vs 4.9%; \(P < 0.0001\)); conversely rates of myocardial infarction (7.4% vs 7.0% vs 6.7%; \(P = 0.66\)) and target vessel revascularization (20.2% vs 22.0% vs 22.4%; \(P = 0.16\)) were not different.

Postprocedural clinical events like arterial hypotension, pulmonary congestion, impairment of renal function, as well as bleeding events, access site complications and mortality rates were more frequently seen in overweight patients than in overweight or obese ones. Different from previous all-comers trials, the Scottish Coronary Revascularisation Register included only patients \((n = 4880)\) receiving elective PCI between 1997 and 2006 without a history of previous known coronary artery disease. During five years of follow-up BMI between 27 and 30 kg/m² was correlated with lower all-cause mortality as compared to other weight groups. Introduction of a blanking time (< 30 d) to exclude periprocedural events and an adjustment to different baseline data did not impact on outcomes of their study\(^{16}\). These results could be confirmed in the APPROACH registry in 31021 patients treated medically \((n = 7801)\), by PCI \((n = 7017)\) or by CABG \((n = 15601)\). In the first group, mortality rates were lower in overweight and obese patients as compared to normal ones. Similar findings were found in both the CABG and PCI group. Interestingly, the use of bare-metal stents (BMS), or any metaanalysis of these single trials revealed an inverse relationship between BMI and clinical outcome after stenting\(^{17}\). In contrast to the above-mentioned results from the balloon angioplasty and BMS era, some other studies from that time do not support the "obesity paradoxon" in patients with both, BMS or DES. Poston et al\(^{19}\) revealed in 1631 patients that normal weight patients were older than the non-normal weight ones at the time of hospital admission\(^{18}\). During one year follow-up mortality and risk for repeat procedures was not different between groups. In the TAXUS trials, 1307 patients were stratified according to BMI and use of stent type (BMS vs DES)\(^{20}\); restenosis rates with use of BMS were higher in obese and overweight patients as compared to normal weight ones (29.2% vs 30.5% vs 9.3%, respectively; \(P = 0.01\)). Although rates for major cardiac events were also significant different in favour of normal weight patients, clinical event rates were not different in patients receiving DES. These findings were underlined by the results of the German DES.DE registry\(^{21}\). At 98 sites in Germany 5806 patients receiving DES in an all-comers design were included and followed over 12 mo. Similar to previous trials baseline comorbidity index was higher in obese patients as compared to overweight and normal weight patient are in-hospital events were similar in all three
groups. One-year follow-up revealed no differences in rates of death (3.3% vs 2.4% vs 2.4%; \( P = 0.17 \)), myocardial infarction (2.8% vs 2.3% vs 2.3%; \( P = 0.45 \)), target vessel revascularization (10.9% vs 11.7% vs 11.6%; \( P = 0.56 \)) and major bleeding (2.5% vs 2.1% vs 2.8%; \( P = 0.53 \)) between normal weight, overweight and obese patients, respectively (Table 1).

**ACUTE CORONARY SYNDROME**

In contrast to stable coronary artery disease an acute myocardial infarction is characterized by a proinflammatory state with different forms of hemodynamic, rhythmogenic and hemostatic disturbances. The phenomenon of an "obesity paradox" has also been evaluated in this patient population; yet, data on a potential link between BMI and clinical events in patients with acute myocardial infarction are scarce and inhomogenous in the literature. Data from the PREMIER and TRIUMPH registries including 6359 patients with acute coronary syndrome were taken to look for any relationship between BMI with survival rate \( P = 0.56 \) and major bleeding \( P = 0.53 \) between normal weight, overweight and obese patients; this however might predominantly result from a technical bias, that cannot be completely corrected by statistical means.

**Table 1 Overview of literature addressing the “obesity paradox” in patients suffering from stable coronary artery disease undergoing coronary angiography and/or revascularization**

| Ref.       | Year | \# | Follow-up (mo) | Mortality | Myocardial infarction | Target vessel revascularization | Renal insufficiency | Vascular complications |
|------------|------|----|----------------|-----------|-----------------------|-------------------------------|---------------------|-----------------------|
| Ellis et al\[24\] | 1996 | 3571 | 12            | +         | -                     | NA                            | -                   | +                     |
| Gurum et al\[20\] | 2002 | 3634 | 60            | +         | NA                    | NA                            | -                   | -                     |
| Gruberg et al\[1\] | 2002 | 9633 | 12            | +         | -                     | -                             | NA                  | +                     |
| Poston et al\[22\] | 2004 | 1631 | 12            | -         | NA                    | NA                            | +                   | -                     |
| Nikolsky et al\[16\] | 2005 | 1301 | 12            | -         | NA                    | -                             | NA                  | NA                    |
| Romero-Corr al et al\[23\] | 2006 | 250152 | 45         | +         | NA                    | NA                            | +                   | +                     |
| Oozepeos et al\[27\] | 2009 | 31021 | 46            | +         | NA                    | NA                            | -                   | -                     |
| Haste et al\[25\] | 2010 | 4880 | 60            | +         | NA                    | NA                            | -                   | -                     |
| Akin et al\[2\] | 2012 | 5806 | 12            | -         | -                     | -                             | -                   | -                     |

NA: Not available.

**RATIONALE FOR THE “OBESITY PARADOX”**

Self-reported obesity increased by 37% from 13.6% to 18.6% among men aged 35-49 since 1970. Simultaneously, epidemiology of other cardiovascular risk factors like arterial hypertension and diabetes increased\[27,28\]. However, mortality attributed to coronary events declined during the last 40 years mainly due to decreased cholesterol levels and damaging smoking habits with greatest reduction seen in overweight and obese patients, and to some degree as a result of more frequent revascularization\[29-31\]. Nevertheless, overweight and obesity, as part of the metabolic syndrome, are still linked to other cardiovascular risk factors, endothelial dysfunction, and inflammation and are often associated with an increased risk of suffering from atherosclerosis.

The key question to answer is how to explain better survival rates from coronary events despite increasing rates of obesity in light of above mentioned correlation. There is an ongoing debate whether the phenomenon of "obesity paradox" is real in the space of coronary artery disease\[10-26\].

Close examination of the current literature revealed that some published and most often retrospective data just claimed a U-shaped nonsignificant trend towards lower survival among underweight patients, compared with normal or mildly overweight patients; this however might predominantly result from a technical bias, that cannot be completely corrected by statistical means.

Detailed analyses reveal that up to 2% of patients who were underweight were likely to suffer from comorbid conditions, including malignancies, heart failure, malnutrition, multiorgan dysfunction, and happened to be significantly older than the normal and obese patients\[10,11,15\]. There is clear evidence that elderly and frail patients have worse clinical outcomes after any coronary event regardless of reperfusion or reperfusion strategy\[32,33\]. It is important to recognise that increasing age with its concomitant comorbidity index results in weight change\[34,35\]. Chronic diseases might lead to gradual weight-loss, which is not taken
into consideration in presented trials. Along these lines, another important confounding observation was the fact that obese patients tended to be diagnosed and treated at an earlier stage than lean patients\cite{36}. Furthermore, the “obesity paradoxon” is clearly challenged by a recent survey on > 130000 patients, revealing that adherence to guidelines was better with higher BMI with regards to standard medication such as aspirin, β-blockers, acetylsalicylsäure inhibitor and angiotensin II receptor blockers, as well as lipid lowering drugs and also an increased likelihood of receiving invasive diagnostic and treatment\cite{15,18,21}. Furthermore overweight and obese patients present in a much more stable status with lack of hemodynamic compromise, lower Killip class, and less impairment of ventricular function. Novel theories to explain the “obesity paradoxon” after PCI have included the suggestion that obese patients have “larger vessels” and outcome after PCI is worse in patients with smaller vessel\cite{37,38}. Antithrombotic medications usually given as standard dosage and not weight adjusted, may be too high in normal weight and underweight patients according to their BMI, resulting in more bleeding events which are associated with higher mortality rate\cite{39}. Similarly, sheath-to-artery size ratio is different in BMI groups resulting in different rates of vascular complications\cite{15}. All these differences in periprocedural events can contribute to improved survival among overweight patients\cite{11,40}. The fact that BMI alone was the only measure of obesity is certainly a limiting factor. There is no information in several trials regarding the distribution of obesity that might be very important, as there is a worse outcome in patients with central obesity\cite{41}. Moreover additional information regarding waist circumference, waist-to-hip ratio and weight changes are missing in several trials describing the “obesity paradoxon”\cite{42,43}. Additionally, all trials supporting the “obesity paradoxon” suffer from the inherent limitation of an observational retrospective registry. Potentially confounding variables such as physical inactivity, unintended weight loss and even socioeconomic factors were not analyzed, and may be the source to further bias, not to mention the short follow-up of these registries. Eventually any potential relation between obesity and in-hospital and short-term survival may be lost the longer patients are followed. Therefore with extended follow-up a cumulative detrimental effect of obesity may manifest over time as increased late mortality\cite{46,47}.

It is sensible to ask what is left to support the so-called “obesity paradoxon”, or is it just a paradoxical concept? Protagonists claim that adipose tissue is being recognized as an endocrine organ\cite{48} that produces soluble tissue necrosis factor receptor with its protective effect\cite{49}. Morbidly obese patients (BMI > 40 kg/m²) certainly have higher adjusted rates of post-PCI mortality that might be due to higher levels of prothrombotic factors as well as elevated levels of plasminogen activator inhibitor-1\cite{50}. On aggregate, while early studies may have suggested an inverse relationship between being underweight with outcomes in heart failure, which led to the assumption of a “obesity paradoxon”, the analysis of the published evidence denies any such “obesity paradoxon” in the context of coronary artery disease and modern coronary interventions. In fact there is no plausible concept to turn away from the classic relationship between risk factors, confounding variables and prognostic outcomes. The limitations of such association studies are not only the lack of a pathophysiologic underpinnings, but moreover the mere association with descriptive notions and the unknown impact of confounding variables. With respect to the neutralizing results from the German DES.DE Registry\cite{21}, the perception of obesity as a protective condition of outcomes after PCI is shattered and the provocative construct of an “obesity paradoxon” evaporates, as such hypothesis was never really substantiated in the clinical setting of coronary artery disease and PCI. Finally, as it turns out, associative studies with little to no statistical evidence lend support to invent a “obesity paradox” which was never supported by biological evidence and seems now shattered by new interpretation of recent clinical data. Any concept will eventually survive only if supported by plausible physiology. In the context of coronary artery disease and PCI there is hardly any plausible explanation and certainly no clinical data to justify an “obesity paradoxon”. 

---

**Table 2** Overview of literature addressing the “obesity paradox” in patients suffering from acute coronary syndrome including cardiogenic shock undergoing coronary revascularization

| Ref. | Year | n   | Follow-up (mo) | Mortality | Myocardial infarction | Target vessel revascularization | Renal insufficiency | Vascular complications |
|------|------|-----|----------------|-----------|-----------------------|-------------------------------|--------------------|----------------------|
| Kosuge et al\cite{25} | 2008 | 3076 | Hospital       | -         | NA                    | NA                            | NA                 | NA                   |
| Kang et al\cite{26} | 2010 | 3824 | 12             | +         | NA                    | NA                            | NA                 | NA                   |
| Camprubi et al\cite{27} | 2012 | 824  | Hospital       | -         | NA                    | NA                            | NA                 | NA                   |
| Buchholz et al\cite{28} | 2012 | 6359 | 12             | +         | NA                    | NA                            | NA                 | NA                   |
| Li et al\cite{29} | 2013 | 1429 | 12             | -         | -                     | -                             | -                  | -                    |
| Shehab et al\cite{30} | 2014 | 4379 | 1              | -         | -                     | -                             | -                  | -                    |
| Akin et al\cite{31} | 2015 | 890  | 12             | -         | -                     | -                             | -                  | -                    |

NA: Not available.
REFERENCES

1. Berghof A, Piscion e T, Reinhold T, Apyian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health 2008; 8: 200 [PMID: 18553389 DOI: 10.1186/1471-2458-8-200].

2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2002. JAMA 2006; 295: 1549-1555 [PMID: 16595758 DOI: 10.1001/jama.295.15.1349].

3. Garrison RJ, Higgins MM, Kannel WB. Obesity and coronary heart disease. Circ Opin Lipidol 1996; 7: 199-202 [PMID: 8883494].

4. Lakha HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716 [PMID: 12460904 DOI: 10.1001/jama.288.21.2709].

5. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gottes A, Grun Lee SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene IK, Pariser T, Pfaffer MA, Starke RD, Tuftel BA. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001; 38: 1581-1583 [PMID: 11695144 DOI: 10.1016/S0735-1097(01)01682-5].

6. De Backer G, Ambrosioni E, Borich-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sants S, Sanso V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10 [PMID: 14555889 DOI: 10.1097/01.hjr.0000087913.96265.e2].

7. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-434 [PMID: 10432328 DOI: 10.1056/NEJM199908053410607].

8. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977 [PMID: 6219830 DOI: 10.1161/01.01.67.5.968].

9. Whitslock G, Leshington S, Sherliker P, Britton A, Kias J, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1-S10 [PMID: 14555889 DOI: 10.1097/01.hjr.0000087913.96265.e2].

10. Minutello RM, Chou ET, Hong MK, Bergmann G, Parikh M, Iacovone F, Wong SC. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the prospective New York State Angioplasty Registry). Am J Cardiol 2004; 93: 1229-1232 [PMID: 15135694 DOI: 10.1016/j.amjcard.2004.01.065].

11. Gruberg L, Weissman NJ, Waksman R, Senej J, Kack KH, Richard G, Nienaber CA. No evidence of “obesity paradox” after treatment with drug-eluting stents in a routine clinical practice: results from the prospective multicenter German DES.DE (German Drug-Eluting Stent) Registry. JACC Cardiovasc Interv 2012; 5: 162-169 [PMID: 22361600 DOI: 10.1016/j.jcin.2011.10.021].

12. Bucholz EM, Raithie SS, Reid KJ, Jones PG, Char PS, Rich MW, Spertus JA. The impact of obesity on the risk of short- and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002; 39: 578-584 [PMID: 11849584 DOI: 10.1016/S0735-1097(01)01802-2].

13. Califf RM, Pieper KS, Lee KL, Van De Werf F, Simes RJ, Armstrong PW, Topol EJ. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101: 2231-2236 [PMID: 10811588 DOI: 10.1161/01.CIR.101.19.2231].

14. Ellis SG, Elliott J, Horrigan M, Raymond RE, Howell G. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996; 78: 642-646 [PMID: 8831397 DOI: 10.1016/S0002-9149(96)00386-4].

15. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes inpatients undergoing percutaneous coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 2002; 39: 834-840 [PMID: 11869849 DOI: 10.1016/S0735-1097(02)01687-X].

16. Haste CE, Padmanabhan S, Slack R, Pell AC, Oldroyd KG, Flapan AD, Jennings KP, Irving J, Eteiba H, Dominiczak AF, Pell JP. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31: 222-226 [PMID: 19687163 DOI: 10.1093/eurheartj/ehp317].

17. Akin I, Schneider H, Nienaber CA, Jung W, Lücke M, Rillig A, Ansan U, Wunderlich N, Birkenmeyer R. Lack of “obesity paradox” in patients presenting with ST-segment elevation myocardial infarction including cardiogenic shock: a multicenter German network registry analysis. BMC Cardiovasc Disord 2015; 15: 67 [PMID: 26162888 DOI: 10.1186/s12872-015-0065-6].
27 Ford ES, Capewell S. Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed leveling of mortality rates. *J Am Coll Cardiol* 2005; 46: 2128-2132 [PMID: 16231039 DOI: 10.1016/j.jacc.2005.05.056]

28 O’Flaherty M, Ford E, Allender S, Scarborough P, Capewell S. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. *Heart* 2008; 94: 178-181 [PMID: 17641070 DOI: 10.1136/hrt.2007.118323]

29 Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2006. *Circulation* 2004; 109: 1101-1107 [PMID: 14993137 DOI: 10.1161/01.CIR.0000118498.35499.B2]

30 Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottek TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. *N Engl J Med* 2007; 356: 2388-2398 [PMID: 17554120 DOI: 10.1056/NEJMoa053935]

31 Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, Narayan KM, Williamson DF. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. *JAMA* 2005; 293: 1866-1874 [PMID: 15844861 DOI: 10.1001/jama.293.15.1868]

32 Holmes DR, White HD, Pieper KS, Ellis SG, Califf RM, Topol EJ. Effect of age on outcome with primary angioplasty versus thrombolyis. *J Am Coll Cardiol* 1999; 33: 412-419 [PMID: 9973021 DOI: 10.1016/S0735-1097(99)00579-8]

33 Halkin A, Singh M, Nikolsky E, Grimes CL, Teheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lysak AJ, Gersh BJ, O’Neill WW, Mehran R, Stone GW. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol* 2005; 45: 1397-1405 [PMID: 15862409 DOI: 10.1016/j.jacc.2005.01.041]

34 Strandberg TE, Strandberg AY, Sylva VM, Pitkälä KH, Tilvis RS, Sirola J, Miettinen TA. Explaining the obesity paradox: cardiovascular risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 2009; 53: 1925-1932 [PMID: 19460605 DOI: 10.1016/j.jacc.2008.12.068]

35 Relman AS, Alpert JS, Angell M, Breyman JL, Collin L, Karger LA, Kornfield J, Lurie S, Marmor J, Oberley TD, Proctor ML, Samet JM, Smith SC Jr, Strohl KP, Weisbrod NR. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 2009; 53: 1925-1932 [PMID: 19460605 DOI: 10.1016/j.jacc.2008.12.068]

36 Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spence E, Moons KG, Tjønneland A, Haakjær Jensen MK, Stegger J, Cavel-Chapelon F, Broutron-Rualut MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijn-Hoffen J, Hallmans G, Weinheil L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez-C, Qurios JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. *N Engl J Med* 2008; 359: 2105-2120 [PMID: 19005195 DOI: 10.1056/NEJMoa0801891]

37 Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. *J Am Coll Cardiol* 1999; 33: 412-419 [PMID: 9973021 DOI: 10.1016/S0735-1097(99)00579-8]

38 Rhodes GG, Kagan A. The relation of coronary disease, stroke, and mortality to weight in youth and in middle age. *Lancet* 1983; 1: 492-495 [PMID: 6131209]

39 Allison DB, Faith MS, Heo M, Kotler DP. Hypothesis concerning the U-shaped relation between body mass index and mortality. *Am J Epidemiol* 1997; 146: 339-349 [PMID: 9270413]

40 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 2004; 89: 2548-2556 [PMID: 15181022 DOI: 10.1210/jc.2004-0395]

41 Mohamed-Ali V, Goodrick S, Bulmer K, Holly JM, Yudkin JS, Coppack SW. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. *Am J Physiol* 1999; 277: E971-1975 [PMID: 1060783]

42 De Pergola G, Pannacciuoli N. Coagulation and fibrinolysis abnormalities in obesity. *J Endocrinol Invest* 2002; 25: 899-904 [PMID: 12508953 DOI: 10.1007/BF03344054]

43 Lu YJ, Wu C, Sun Y, Jiang D, Zhang B, Ren L, Gao Y, Hu Y, Yang G, Guan Q, Tian W, Zhang H, Guo L, Qi G. Obesity paradox: clinical benefits not observed in obese patients with ST-segment elevation myocardial infarction: a multicenter, prospective, cohort study of the northern region of China. *Int J Cardiol* 2013; 168: 2549-2560 [PMID: 23642605 DOI: 10.1016/j.ijcard.2013.03.169]

44 Shehab A, Al-Dabbagh B, AlHabib K, Alshikh-Kali-Ali A, Almahmeed W, Sulaiman K, Al-Motarreb A, Suwaidi JA, Hersi A, AlFaleh H, Asaad N, AlSaif S, Amin H, Alhanabi M, Magelkerke N, Abdulle A. The obesity paradox in patients with acute coronary syndrome: results from the Gulf RACE-2 study. *Angiology* 2014; 65: 585-589 [PMID: 23921507 DOI: 10.1177/0001134413479678]

P- Reviewer: Lee TM, Petix NR
S- Editor: Ji FF
L- Editor: A
E- Editor: Lu YJ
